• Je něco špatně v tomto záznamu ?

A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea

M. Schaller, L. Kemény, B. Havlickova, JM. Jackson, M. Ambroziak, C. Lynde, M. Gooderham, E. Remenyik, J. Del Rosso, J. Weglowska, R. Chavda, N. Kerrouche, T. Dirschka, S. Johnson,

. 2020 ; 82 (2) : 336-343. [pub] 20190529

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, klinické zkoušky, fáze IV, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025234

BACKGROUND: Randomized controlled studies of combination therapies in rosacea are limited. OBJECTIVE: Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. METHODS: This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA] score, 4) to receive either IVM and DMR (combination arm) or IVM and placebo (monotherapy). RESULTS: A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs -73.6% for monotherapy [P = .032]) and IGA score (P = .032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2% [P = .006]) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were well tolerated. LIMITATIONS: The duration of the study prevented evaluation of potential recurrences or further improvements. CONCLUSION: Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in cases of severe rosacea.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025234
003      
CZ-PrNML
005      
20201222155126.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jaad.2019.05.063 $2 doi
035    __
$a (PubMed)31150711
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Schaller, Martin $u Department of Dermatology, Tübingen University Hospital, Tübingen, Germany. Electronic address: martin.schaller@med.uni-tuebingen.de.
245    12
$a A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea / $c M. Schaller, L. Kemény, B. Havlickova, JM. Jackson, M. Ambroziak, C. Lynde, M. Gooderham, E. Remenyik, J. Del Rosso, J. Weglowska, R. Chavda, N. Kerrouche, T. Dirschka, S. Johnson,
520    9_
$a BACKGROUND: Randomized controlled studies of combination therapies in rosacea are limited. OBJECTIVE: Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. METHODS: This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA] score, 4) to receive either IVM and DMR (combination arm) or IVM and placebo (monotherapy). RESULTS: A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs -73.6% for monotherapy [P = .032]) and IGA score (P = .032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2% [P = .006]) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were well tolerated. LIMITATIONS: The duration of the study prevented evaluation of potential recurrences or further improvements. CONCLUSION: Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in cases of severe rosacea.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a tobolky $7 D002214
650    _2
$a léky s prodlouženým účinkem $x aplikace a dávkování $7 D003692
650    _2
$a doxycyklin $x aplikace a dávkování $7 D004318
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ivermektin $x aplikace a dávkování $7 D007559
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a spokojenost pacientů $7 D017060
650    _2
$a placeba $x aplikace a dávkování $7 D010919
650    _2
$a kvalita života $7 D011788
650    _2
$a rosacea $x komplikace $x diagnóza $x farmakoterapie $7 D012393
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a pleťový krém $x aplikace a dávkování $7 D063465
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Kemény, Lajos $u Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
700    1_
$a Havlickova, Blanka $u Dermatology Center, Prague, Czech Republic.
700    1_
$a Jackson, J Mark $u Division of Dermatology, University of Louisville, Louisville, Kentucky; Forefront Dermatology, Louisville, Kentucky.
700    1_
$a Ambroziak, Marcin $u Ambroziak Clinic, Warsaw, Poland.
700    1_
$a Lynde, Charles $u Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Gooderham, Melinda $u SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
700    1_
$a Remenyik, Eva $u Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Del Rosso, James $u JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada.
700    1_
$a Weglowska, Jolanta $u Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland.
700    1_
$a Chavda, Rajeev $u Medical Evidence, Galderma S.A., Vevey, Switzerland.
700    1_
$a Kerrouche, Nabil $u Galderma R&D, Sophia Antipolis, France.
700    1_
$a Dirschka, Thomas $u CentroDerm-Clinic, Wuppertal, Germany; Faculty of Health, University of Witten-Herdecke, Witten, Germany.
700    1_
$a Johnson, Sandra $u Johnson Dermatology, Fort Smith, Arkansas.
773    0_
$w MED00002961 $t Journal of the American Academy of Dermatology $x 1097-6787 $g Roč. 82, č. 2 (2020), s. 336-343
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31150711 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155122 $b ABA008
999    __
$a ok $b bmc $g 1599379 $s 1115920
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 82 $c 2 $d 336-343 $e 20190529 $i 1097-6787 $m Journal of the American Academy of Dermatology $n J Am Acad Dermatol $x MED00002961
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace